title: Effect of hydroxyapatite nanoparticles on the ultrastructure and function of hepatocellular carcinoma cells in vitro.
abstract: The interaction of Bel-7402 hepatocellular carcinoma cells (HCC) as a single cell suspension with hydroxyapatite (HAP) nanoparticles was investigated. It was observed by an inverted microscope that the cells were still homogeneously distributed in the culture medium after 24 h. A TEM analysis showed that the HAP nanoparticles attached to the Bel-7402 cells were finally swallowed by the cells after 4 h, and induced ultrastructural changes of the cells after 4 days. A MTT assay and cell count test for the HAP nanoparticles of various concentrations from 0.14 to 0.56 mmol L(-1) showed that the HAP nanoparticles at a concentration of 0.56 mmol L(-1) induced the strongest effect on the inhibition of Bel-7402 cell proliferation and induced a dramatic decline in cell numbers. Proliferation of Bel-7402 was inhibited by more than 70%, compared to the control. A cell cycle analysis revealed that HAP can arrest Bel-7402 cells at the G1 phase with increasing effect over time. These findings demonstrated that HAP can enter into HCC very easily, change their ultrastructure, and evidently suppress their proliferation.
authors.affiliation: Center of Biomedical Material and Engineering, Wuhan University of Technology, Wuhan 430070, People's Republic of China.
authors.forename: Mei-Zhen
authors.initials: MZ
authors.lastname: Yin
authors.forename: Ying-Chao
authors.initials: YC
authors.lastname: Han
authors.forename: Ingo W
authors.initials: IW
authors.lastname: Bauer
authors.forename: Pei
authors.initials: P
authors.lastname: Chen
authors.forename: Shi-Pu
authors.initials: SP
authors.lastname: Li
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D017886:Durapatite / Q000008:administration & dosage* / Q000737:chemistry*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D008422:Materials Testing; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry* / Q000648:ultrastructure; D010316:Particle Size
chemical_list: D017886:Durapatite